Elena K. Schneider Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences Monash University Biography Publications Institution JoVE Articles Elena K. Schneider has not added a biography. If you are Elena K. Schneider and would like to personalize this page please email our Author Liaison for assistance. Publications Cationic Acrylate Oligomers Comprising Amino Acid Mimic Moieties Demonstrate Improved Antibacterial Killing Efficiency Journal of Materials Chemistry. B, Materials for Biology and Medicine. Jan, 2017 | Pubmed ID: 28966792 Gelofusine Ameliorates Colistin-induced Nephrotoxicity Antimicrobial Agents and Chemotherapy. Sep, 2017 | Pubmed ID: 28923868 Aminoglycoside Concentrations Required for Synergy with Carbapenems Against Pseudomonas Aeruginosa Determined Via Mechanistic Studies and Modeling Antimicrobial Agents and Chemotherapy. Sep, 2017 | Pubmed ID: 28893782 Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes ACS Infectious Diseases. Aug, 2017 | Pubmed ID: 28695731 Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]-Colistin Prodrugs Through Copper-Mediated Photoinduced Living Radical Polymerization Bioconjugate Chemistry. Jul, 2017 | Pubmed ID: 28657722 Deficiency in Outer Dense Fiber 1 is a Marker and Potential Driver of Idiopathic Male Infertility Molecular & Cellular Proteomics : MCP. Jun, 2017 | Pubmed ID: 28572402 Antibiotic-non-antibiotic Combinations for Combating Extremely Drug-resistant Gram-negative 'superbugs' Essays in Biochemistry. Feb, 2017 | Pubmed ID: 28258235 A Traceless Reversible Polymeric Colistin Prodrug to Combat Multidrug-resistant (MDR) Gram-negative Bacteria Journal of Controlled Release : Official Journal of the Controlled Release Society. Aug, 2017 | Pubmed ID: 28174100 Plasma Protein Binding Structure-Activity Relationships Related to the N-Terminus of Daptomycin ACS Infectious Diseases. Mar, 2017 | Pubmed ID: 28142234 From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators Microbial Drug Resistance (Larchmont, N.Y.). Jul, 2017 | Pubmed ID: 27935770 Development of HPLC and LC-MS/MS Methods for the Analysis of Ivacaftor, Its Major Metabolites and Lumacaftor in Plasma and Sputum of Cystic Fibrosis Patients Treated with ORKAMBI or KALYDECO Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. Dec, 2016 | Pubmed ID: 27792891 Deficiency in Outer Dense Fiber 1 Is a Marker and Potential Driver of Idiopathic Male Infertility Molecular & Cellular Proteomics : MCP. 12, 2016 | Pubmed ID: 27770032 The Plasma Protein Binding Proteome of Ertapenem: A Novel Compound-Centric Proteomic Approach for Elucidating Drug-Plasma Protein Binding Interactions ACS Chemical Biology. 12, 2016 | Pubmed ID: 27682196 A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes ACS Infectious Diseases. May, 2016 | Pubmed ID: 27627202 An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI ACS Infectious Diseases. Jul, 2016 | Pubmed ID: 27626100 Molecular Characterisation of the Haemagglutinin Glycan-Binding Specificity of Egg-Adapted Vaccine Strains of the Pandemic 2009 H1N1 Swine Influenza A Virus Molecules (Basel, Switzerland). Jun, 2015 | Pubmed ID: 26056814 Drug-drug Plasma Protein Binding Interactions of Ivacaftor Journal of Molecular Recognition : JMR. Jun, 2015 | Pubmed ID: 25707701 Optimierte LC-MS/MS-Methode für die Hochdurchsatz-Analyse der klinischen Proben von Ivacaftor, seinen Hauptmetaboliten und Lumacaftor in biologischen Flüssigkeiten von Mukoviszidose-Patienten Elena K. Schneider1, Felisa Reyes-Ortega1, Jian Li1,2, Tony Velkov1 1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 2Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University JoVE 56084 Medicine
Optimierte LC-MS/MS-Methode für die Hochdurchsatz-Analyse der klinischen Proben von Ivacaftor, seinen Hauptmetaboliten und Lumacaftor in biologischen Flüssigkeiten von Mukoviszidose-Patienten Elena K. Schneider1, Felisa Reyes-Ortega1, Jian Li1,2, Tony Velkov1 1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 2Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University JoVE 56084 Medicine
